Vertex Pharmaceuticals Beats Q3 Earnings Estimates, Projects Strong 2024 Revenue
Vertex Pharmaceuticals (NASDAQ: VRTX) has reported impressive third-quarter earnings for fiscal year 2024, exceeding EPS and revenue estimates. With an EPS of $4.38 and revenue of $2.77 billion, the company showcases strong growth potential in the biotechnology sector. As it projects full-year revenues between $10.80 billion and $10.90 billion, investors are keenly watching Vertex’s innovative therapies and market strategies.
Vertex Pharmaceuticals Reports Strong Q1 2024 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported a 13% increase in product revenue in the first quarter of 2024, driven by strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label extensions. With net product revenue rising both in the U.S. and internationally, Vertex’s strategic moves, including the recent acquisition of Alpine Immune Sciences, are closely watched by investors and industry analysts.